netivudine
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00002315)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Reverse transcriptaseINHIBITOR
Reverse transcriptase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC#Cc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)[nH]c1=O- Mol. weight
- 282.25 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1097615 ↗
Also known as
- 1-(beta-d-arabinofuranosyl)-5-(1-propynyl)uracil
- 5-propynyl-1-(beta-arabinofuranosyl)uracil
- 5-propynylarabinofuranosyluracil
- 5-propynyl-arau
- 882c
- 882c87
- 882c87
- 882c87
- netivudine
- netivudine
- netivudine
- netivudine
- netivudine
- pyarau
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00002315 | Phase 3 | Nov 2, 1999 | Glaxo Wellcome |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Glaxo Wellcome | For profit | 1 | 1 | 1 | 1999 |
1 organizations
Page 1 / 1